ETON
BUYNeutralComposite
73.20
Technical
92.90
Fundamental
60.10
Rank
—
Price
62.67
Hurst
0.51
As of
Aug 28, 2026
Daily
Eton Pharmaceuticals, Inc.
HealthcareDrug Manufacturers - Specialty & GenericEton Pharmaceuticals is a rare disease-focused drug developer with an established portfolio of marketed treatments addressing conditions such as growth hormone deficiency, adrenal disorders, Wilson disease, metabolic disorders, and tyrosinemia. The company also maintains a pipeline of investigational candidates in advanced stages targeting diabetes insipidus, neonatal diabetes, and adrenal insufficiency, among others. Founded in 2017 and headquartered in Illinois, the company specializes in acquiring and commercializing therapies for orphan indications.
Market cap
$1.6B
P/E (trailing)
146.33
P/E (forward)
22.12
PEG ratio
—
Dividend yield
—
Beta
0.90
52w range
14.27 – 66.37
Return on equity
+35.97%
Profit margin
+12.02%
Revenue growth
+98.60%
Earnings growth
—
Price history
1Y: 57.07 (+209.2%) · range 14.35–64.43
Cycle position
59/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 14 · NOT READY · exit proximity 35
Conviction
23/ 100 · maturity 100%
VScore.4010
Buildup.2033
EMA entry setup.2514
Fundamentals.1560
Volume profile
POC
30.74
Price vs POC
+85.7%
Overhead supply
21%
Runway
open sky
Value area 22.38–47.01 · 21% of 120d volume overhead · moderate overhead
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.033 | Sep 11, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -4.52% | +3.65% | 9/20d |
| 40d | -4.52% | +3.65% | 9/40d |